WHO EMRO | Management of patients with metastatic colorectal cancer in Lebanese hospitals and assoc PDF version Anna Maria Henaine, 1,2,5 Georges Chahine, 4 Marcel Massoud, 4,9 Pascale Salameh, 5,7 Sanaa Awada, 5 Nathalie Lahoud, 8 Edward Elias, 4 Mansour Salem, 4 Souheir Ballout, 5 Daniel Hartmann, 1,2 Gilles Aulagner 1,2,3 and Xavier Armoiry 1,2,3,6 ¹Université Claude Bernard Lyon 1, Lyon, France. ²UMR–CNRS 5510/MATEIS, Lyon, France 3 Hospices Civils de Lyon, Hôpital Édouard-Herriot, Service Pharmaceutique, Lyon, France. 4 Hôtel Dieu de France and St Joseph University, Beirut; Hôpital Notre Dame de Secours, Byblos, Lebanon. 5 Clinical and Epidemiological Research Laboratory, School of Pharmacy, Lebanese University, Beirut, Lebanon. 6 University of Lyon, Claude Bernard University Lyon,3 Lyon School of Pharmacy, Public Health Department, Lyon, France, 7 Pharmacy Practice Department, School of Pharmacy, Lebanese American University, Beirut, Lebanon. 8 Doctoral School of Sciences and Technologies, Lebanese University, Beirut, Lebanon. 9 Holy Spirit University,Kaslik, Lebanon. (Correspondence to: Anna Maria Henaine: annamaria.henaine@gmail.com). Abstract 1 / 19